Pharmaceuticals, Biotechnology and Life Sciences
Takeda and TiGenix reported on Tuesday that the Swiss Agency for Therapeutic Products (Swissmedic) has accepted for review the file on investigational compound Cx601 to treat complex perianal fistulas in patients with Crohn’s disease.
Johnson & Johnson <JNJ.N>, Novartis AG <NOVN.S> and Takeda Pharmaceutical Co Ltd <4502.T> have expressed interest in a buyout of the controlling stake that two families have in Brazilian drugmaker Hypermarcas SA <HYPE3.SA>, two people with knowledge of the matter said on Monday
Arix Bioscience and Takeda will work together to combine complementary skills and experience across important therapeutic areas in a strategic deal.
Takeda and TiGenix have presented new data from the Phase 3 ADMIRE-CD clinical trial of treatment refractory complex perianal fistulas in patients with Crohn’s disease at the 12th Congress of the European Crohn’s and Colitis Organisation (ECCO).
Takeda has ensured the signature to buy USA-based drugmaker focused on producing cancer treatments, Ariad Pharmaceuticals for about $5.2 billion, or $24 per share in cash for stockholders.
On January 4, 2017, TiGenix received a transparency notification from related companies Takeda Pharmaceutical Company Limited/Takeda Pharmaceuticals International AG, following…
Belgian based biopharmaceutical company TiGenix has exercised the option granted by Takeda under the licensing agreement to make a EUR10…
Teva and Takeda are forming a new joint venture to operate in Japan
Teva Pharmaceutical Industries Ltd. announced on Monday that its glatiramer acetate injection was approved by the Japanese Ministry of Health, Labour and Welfare (MHLW)…
Takeda Pharmaceutical Company Limited will participate in WIPO Re:Search, a consortium to accelerate research and development (R&D) of new drugs, vaccines,…